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esponsibility of InstAbstract Governments that procure pharmaceutical products from an Essential Medicine List (EML)
bear special responsibility for the quality of these products. In this article we examine the possibility of
developing a pharmaceutical product quality risk assessment scheme for use by government procurement
ofﬁcials. We use the Chinese EML as a basis, and US recall data is examined as it is publically available.
This is justiﬁed as the article is only concerned with inherent product quality risks. After establishing a
link between Chinese essential medicines and those available in the US, we examine US recall data to
separate product speciﬁc recalls. We conclude that, in addition to existing manufacturing based risks, there
are two other product speciﬁc risks that stand out from all others, degradation and dissolution failure.
Methodology for relative product risk for degradation is needed to be developed and further work is
required to better understand dissolution failures which largely occur with modiﬁed-release solid oral
products. We conclude that a product speciﬁc quality risk proﬁle would be enhanced by including a risk
assessment for degradation for all products, and in the case of solid oral products, dissolution.
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(1)The Chinese Essential Medicine List consists of 317 chemical and
biological products, 203 traditional Chinese medicines and includes all
other herbal slices or ﬂakes not speciﬁcally listed.
Wei Xu et al.801. Introduction
Pharmaceutical product development and commercial manufactur-
ing are subject to government regulation and oversight in virtually
every country. This oversight includes review and approval of new
products and site inspection for quality management (CGMP) of
pharmaceutical production, packaging, storage, and distribution
facilities, in addition to oversight of drug product promotional
activities. Regulatory authorities charged with oversight of the
pharmaceutical industry have limited resources with which to carry
out their mission. As the pharmaceutical industry continues to
grow and globalize, the issue of the resources available to
regulatory authorities has become more critical. Many regulatory
authorities have addressed the resources problem by introducing
risk based inspectional systems in which each facility is rated for
relative risk and inspectional resources are preferentially directed
to those facilities with high manufacturing risk proﬁles. For
example, the European Medicines Agency (EMA) uses an assess-
ment of Site Complexity, Process Complexity, and Product
Complexity to generate an overall risk proﬁle for a given facility1.
While these risks based inspectional systems are appropriate where
governments act primarily to oversee industry, they say nothing about
individual products, only about product classes and/or facility types.
For example, parenteral products are high risk because product failure
generally has serious health consequences. However, for some
governments their responsibilities extend to individual products in
addition to the overall state of compliance of the industry. Countries
that institute an Essential Medicine List (EML) must source EML
products for use in the healthcare system. This raises the question of
product quality based risk assessment in determining that individual
sources of supply to government of EML products are in compliance
and producing product that is ﬁt for use.
At present the only product based risk assessment that has been
widely applied is the Biopharmaceutics Classiﬁcation System (BCS).
This system classiﬁes “bioequivalence risk” based on in vitro
solubility and in vivo permeability of the drug. As such it is only
applicable to immediate-release solid oral dosage forms. While this
group represents the largest class of dosage forms, it does not help in
assigning product risk factors to other dosage forms or to products in
the same BCS class and subclass. The BCS system has been used to
classify “bioequivalence risk” for products in WHO's model EML2
and top oral drugs in countries worldwide3,4. Not every orally
administered drug has been assigned to a BCS class and some
BCS class assignments are proposed based on in vitro measures of
lipophilicity5,6. These products still need in vivo permeability data to
enable a BCS class assignment for regulatory purposes.
China has adopted an EML as part of the reform of the
healthcare system that commenced in 20097–9. The intention of the
EML is to reduce inappropriate use of drugs and to improve access
to safe and effective drugs for the majority of treatment require-
ments8–11. The government procures the supply of EML products
and provides them to health-care institutions10,11. Since the
government makes the product acquisition decisions, the govern-
ment bears more than the usual responsibility for these products
being ﬁt for use. For this reason regulatory authorities in countries
where the government procures product for an EML have a special
interest in assessing the state of compliance of EML product
providers. Obviously such large supply contracts are very attrac-
tive to pharmaceutical manufacturing companies and competition
to secure this business is ﬁerce11,12. Although government wants
the best price, it must also ensure that the product it procures is
good as the quality of EML drugs will have a major impact onhealthcare outcomes. It would therefore be of interest to the
relevant regulatory authority to be able to rank the relative “by
product” quality risk proﬁle for each of the products on the EML.
For the rest of this work the Chinese EML will be used as a
reference point. However, this work is applicable to all countries
where the government maintains an EML and procures EML
products for use in the healthcare system.2. Method
The Chinese government's EML was ﬁrst promulgated in 2009 as
part of a larger healthcare overhaul. The most recent version (2012
edition) of the list13 contains 317 chemical and biological drug
products of a total of 520 where the other products are traditional
Chinese medicines (TCMs)(1). Although in theory risk assessment
can be applied to TCM products, the focus in this assessment is on
the chemical and biological products as many of these products are
available in many other regulated markets whereas regulated TCM
products are usually only available in China14,15.
In order to ﬁnd publically available data for analysis, the US
FDA's Approved Drug Products with Therapeutic Equivalence
Evaluation list, the so-called Orange Book, was used to determine
how many of the products on the EML were also approved in the US.
On the Chinese EML, chemical and biological products are listed as
chemical ingredients by International Nonproprietary Names (INN)
for their English names. The FDA Orange Book16 was searched for
the English names of the Chinese Essential Medicines to see if they
were also approved by FDA. This search found that two thirds of the
products on the EML were also approved in the US.
Once we had determined from the Orange Book that the US market
was representative of the Chinese EML products, we turned to sources
of publically available information which might be used to judge the
performance of individual products on the US market. There are two
main sources, Adverse Drug Event (ADE) reporting17 and Drug
Recalls18. ADE data is massive19 but almost all reports do not contain
enough data to determine whether an ADE is related to a speciﬁc
product defect. Many ADEs are due to the speciﬁc pharmacological
effects of drug ingredients rather than controllable product quality
failures. For this reason, we decided to focus on the recall information.
In the United States, drug recalls are almost always voluntary
actions taken by a ﬁrm to remove a product from the market20.
Recalls may be conducted on a ﬁrm's own initiative, by FDA
request or by FDA order under statutory authority. Drug recalls are
classiﬁed into three classes21 determined by the possible health
consequences of the particular product failure. Recalls of Foods,
Drugs, Biologics and Devices are published weekly on the FDA
website. We collected drug recall information from calendar years
2011, 2012 and 2013. An event ID is assigned by FDA to every
speciﬁc recall event and used for tracking purposes22.
A recall event may include more than one recalled product.
Where applicable, each recall event was further divided into
individual recalled products. For each of the recalled products, a
recall reason description of one or two sentences is given
following a generalized phrase on the FDA website. Recalled
products were examined individually to see if the recall reasons
were detailed and clear enough for further analyses to determine
the underlying cause of the recall. Four classes of recalled products
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the reason for recall was not speciﬁc to the product but rather
general in nature. Compounded products were also excluded as
these are not produced by conventional commercial manufactur-
ing23–25 and would not or should not be used as sources for EML
procurement.
These recalled products were then divided into eight major groups
based on more detailed causes as deﬁned from the descriptions given
by FDA. Products related to packaging were excluded because it is not
viewed as a product speciﬁc factor. Recalled products related to CGMP
failures, contamination, or temperature abuse were excluded because
they are categorized as facility related and general to all drug products.
For the recalled products related to visual crystalline particulates due to
inspection failures or upon reconstitution, it was not possible to tell if
they were due to product formulation problems, so they were obviated
from further analyses. We checked the drug types of the remaining
chosen recalled products and products not relevant to the Chinese EML
were excluded.
This analysis showed that stability caused impurities/degradation/
subpotent effects is the most frequent product speciﬁc risk. The
International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH) has
released 6 guidelines on stability testing26 and EU, Japan and US
have incorporated these guidelines on stability testing into regulation.
However, these guidelines only give very general guidance on
carrying out stability indicating tests to get new drug substances,
products and dosage forms approved. The recall analyses identiﬁed
that some products still failed degradation or impurities speciﬁcations
in routine commercial manufacture although all of them must have
passed this kind of testing during application for approval. In order to
get the drugs approved, manufacturers carry out so-called accelerated
or stressed degradation test which can include severe stress condi-
tions. The purpose is to demonstrate that the analytical methodology
can separate degradants that arise from chemical decomposition. For
our purpose we need testing under normal or mild conditions which
could better ascertain the real life chemical stability characteristics of
drug products, in particular to tell whether a drug might degrade or
appear stable under mild stress.
To determine if any research exists on stability testing methods
under less harsh conditions, 8 drugs were randomly chosen from
the EML that had also been recalled in the US from our analysis of
the recall data. Using these 8 drugs, a literature search was
conducted to see what could be determined about chemical
stability and stability testing.
For the products recalled due to "presence of foreign sub-
stances" in parenteral solutions, many of these recalls suggested
that the particulate matter was related to packaging components,
e.g., glass vials, rubber stoppers and silicone lubricant. As it is not
possible to tell if product speciﬁc factors, such as product
formulation, were a causative factor in any of these recalls they
were excluded.
Then dissolution is the second most frequent product speciﬁc
risk. To assess the signiﬁcance of the dissolution failures, IMS
data on volume of product sold in the US market were categorized
by dosage form type for the years 2011, 2012, and 2013, the same
years as the recall data were analyzed. Some of the IMS data were
excluded as it did not identify dosage form, did not specify that it
was a drug, or was otherwise not relevant (products simply
listed as sodium, magnesium and calcium; botanicals; nutrients;
probiotics; drugs for pets; minerals; cosmetics; undeﬁned). There
is little difference between the 2011, 2012, and 2013 product
volume data, so 2013 is taken as representative for the purpose ofdetermining relative product volume market size for solid oral
products.3. Results
3.1. US market as a valid representative of the Chinese EML
products
220 essential medicines out of the Chinese EML, total of 317
(69.4%) were also approved in the US which is taken to mean that
product performance of marketed products in the US is represen-
tative of the Chinese EML.
3.2. Getting a ﬁt-for-purpose list of recalled products
From calendar year 2011 through 2013, a total of 1070 recall
events were collected from the US database. Dividing them into
individual recalled products, yielded a total of 4062 products
recalled. Individual recalled products in four classes of recalled
products were excluded from the data pool because the recall
reasons were general to all pharmaceutical products and not
ascribable to the individual product. This left 1524 recalled
products for further analyses. The number of recalled products
and the reasons for which they were excluded are listed in Table 1.
As is shown in Table 2, the remaining recalled products were
divided into eight major groups based on more speciﬁcally
identiﬁed causes. 501 recalled products related to packaging,
331 related to CGMP failures, 174 for contamination, 10 for
storage temperature failures, 8 related to visual crystalline parti-
culates and 2 reconstitution failures were excluded from the study
database. The remaining products were then classiﬁed as 274
stability failures and 224 manufacturing failures most probably
due to drug product speciﬁc problems. These 498 recalled products
became the working database for the study and then each was
evaluated to determine if there are actual product speciﬁc causes
for each product in these two major groups. 41 products in product
types that are not included in the EML (dental care products, sun
screen products, cosmetics such as for acne treatment, animal
medicine and ﬁrst aid kits) were excluded resulting in a ﬁnal list/
data pool of 457 products for further evaluation.
3.3. Stability-caused impurities/degradation/subpotent as the
most frequent and signiﬁcant product speciﬁc risk
The remaining 457 recalled products were reorganized into groups
based on the actual underlying cause of the recall as it was
determined. As shown in Table 3, 140 recalled products were
recalled due to stability failures for impurities/degradation/sub-
potent reasons, which ranked ﬁrst among all the recall reasons,
approximately 31% of the total number.
Table 4(a) shows the 22 drug products recalled due to stability
failures for impurities/degradation/subpotent that are also on the
Chinese EML. Eight of these products were chosen at random to
conduct a literature search to see if any methodology exists for
testing pharmaceutical product stability under normal or less harsh
conditions.
The literature search results are summarized in Table 5. The
stability indicating methods generally use separative chromato-
graphic methodologies such as HPLC, DAD, TLC, UPLC, LC,
HPTLC and HPTL, and are used singly or in combinations to
Table 1 Recalls eliminated from the original list.
Eliminated class of recall No. Recall reason given on FDA website Reason for elimination
Contain ingredients without an
approved ANDA/NDA
241  Marketed without an ANDA/NDA
(225)
 CGMP deviations (10)
 Misbranded(6)
The products in question were not approved by FDA
Compounding failures 1770  Lack assurance of sterility (610)
 Penicillin cross contamination
(850)
 Methylprednisolone compounding
failure (298)
 CGMP deviations (10)
 Chemical contamination (1)
 Microbial contamination (1)
The products in question were not approved by FDA. These
compounding pharmacies do not (or should not) provide
drug product for sale under normal commercial conditions
Penicillin cross contamination due
to non-compounding failures
5  Penicillin cross contamination (5) Any product can become cross contaminated. It is a facility
or procedure issue which has nothing to do with the
particular product.
Due to reasons couldn't be decided
according to the given
information
522  Microbial contamination (260)
 Subpotent (59)
 Impurities/degradation (49)
 Presence of particulate matter (40)
 Contraceptive tablets out of
sequence (23)
 Failed dissolution speciﬁcations
(21)
 Lack assurance of sterility (17)
 Discoloration (13)
 CGMP deviations (8)
 Misbranded (8)
 Superpotent (7)
 Presence of precipitate (3)
 Failed content uniformity require-
ments (3)
 Failed tablets/capsules speciﬁca-
tions (3)
 Does not meet monograph (2)
 Failed PH speciﬁcations (2)
 Does not deliver proper metered
dose (2)
 Defective delivery system (1)
 Due to an abundance of caution (1)
The cited reason on FDA website were too vague to
determine anything about the underlying reason for the
recall
Wei Xu et al.82carry out assay and related substance/degradation product deter-
minations. The corresponding method parameters, such as column
type, ﬂow rate, mobile phase, detection wavelength and run time,
etc. are optimized. The linearity, ranges, precision, accuracy,
selectivity, detection and quantiﬁcation limit, recovery rates and
repeatability are validated. Then accelerated/stressed degradation
tests are carried out under acid hydrolysis, alkali hydrolysis,
oxidative degradation, dry heat degradation and photolytic degra-
dation conditions. Such tests usually claim that they could resolve
the degradants successfully.
However, as summarized in Table 5, these methods apply many
and varied chemical stress conditions to carry out accelerated
degradation tests. They thus yield diverse and sometimes contra-
dicting results, even though the methodology claims to be
validated according to the ICH guidelines. The literature search
did not ﬁnd any literature directed to determining the relative risk
of drug substance or drug product degradation. The methods are
entirely directed at stress testing for analytical method develop-
ment. There is a need for methodology that is predictive ofchemical sensitivity of drugs and drug products so that a risk rating
can be assigned to this failure mode for individual products.3.4. Stability-caused dissolution failures as another frequent
and signiﬁcant product speciﬁc risk
Recalls listed as due to "presence of foreign substances" were
excluded from the data pool because it is not possible to tell if
product speciﬁc factors such as product formulation were a
causative factor.
Stability related dissolution failures were then the second most
frequent product speciﬁc risk. Table 4(b) shows the 15 products that
were recalled for dissolution failure that are also on the Chinese
EML. As shown in Table 6(b), an examination of the 52 products in
the data pool that were recalled for dissolution related failures found
that this issue is correlated to dosage form and most frequently
happened to immediate- or extended-release oral dosage forms.
In order to analyze the signiﬁcance of dissolution failures, the
data from IMS Health on pharmaceutical products sold on the US
Table 2 Reclassiﬁcation of the remaining 1524 recalls into 8 major groups.
Group No. Recall reason given on FDA website Group No. Recall reason given on FDA website
Packaging/
labeling
501  Label mix-up/misbranded/incorrect labeling/wrong barcode (226)
 Presence of foreign substances/ particulate matter (81)
 Lack assurance of sterility (66)
 Adulterated presence of foreign tablets/capsules (41)
 Defective container/container leakage (33)
 CGMP deviations (28)
 Miscalibrated/defective delivery system (7)
 Short ﬁll (6)
 Unit dose mispackaging (4)
 Superpotent (4)
 Does not deliver proper metered dose (2)
 Impurities/degradation (2)
 Discoloration (1)
Stability failures 274  Impurities/degradation (82)
 Subpotent (67)
 Failed dissolution speciﬁcations (50)
 Stability data doesn't support expiration date (24)
 Product lacks stability/failed stability speciﬁcations (18)
 CGMP deviations (15)
 Presence of particulate matter (6)
 Lack assurance of sterility (6)
 Failed pH speciﬁcations (2)
 Microbial contamination (1)
 Superpotent (1)
 Failed moisture limit (1)
 Failed tablets/capsules speciﬁcations (1)
CGMP failures 331  CGMP deviations (297)
 Lack assurance of sterility (18)
 Impurities/degradation (4)
 Microbial contamination (3)
 Subpotent (3)
 Superpotent (2)
 Using materials not listed in FDA application (2)
 Failed dissolution speciﬁcations (1)
 Incorrect product formulation (1)
Manufacturing failures 224  Presence of foreign substances/particulate matter (73)
 Failed tablets/capsules speciﬁcations (44)
 Miscalibrated/defective delivery system (22)
 Failed content uniformity speciﬁcations (19)
 Superpotent (18)
 Subpotent (12)
 Cross contamination/other products discoloration (11)
 Presence of precipitate (8)
 Resuspension problems (5)
 Crystallization (4)
 Tablet/capsules imprinted with wrong ID (4)
 Does not deliver proper metered dose (1)
 Defective product (1)
 Discoloration (1)
 Lack of assurance of sterility (1)
Contamination 174  Microbial contamination (93)
 Chemical contamination (57)
 Lack assurance of sterility (13)
 Cross contamination (9)
 Oversulfated chondroitin sulfate (2)
Temp abuse 10 Temperature abuse (10)
Precipitate 8 Crystallization (8)
Reconstitution 2 Crystallization (2)
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Table 3 Determined to be product speciﬁc risks.
Essential recall reasons Stability Manufacturing Laboratory impurity testing failure Total
Impurities/degradation/subpotent 140 140
Presence of foreign substances 72 72
Dissolution 52 52
Tablet weight 50 50
Content uniformity 4 13 17
Peel force failure 12 12
Cross contamination/other products discoloration 11 11
Subpotent 10 10
API precipatate 9 9
Presence of particulate matter 6 3 9
Failed stability speciﬁcations 8 8
Superpotent 1 7 8
Adhesion failure 6 6
CGMP deviations 5 5
Impurity 4 4
Leaking capsules 4 4
Crystallization 4 4
Friability 4 4
Logo incorrect 4 4
Particle size 4 4
AET failure 3 3
Viscosity 3 3
Microbal contamination 2 2
Packaging 2 2
PE failure 2 2
Sterility 1 1 2
Failed pH speciﬁcation 2 2
Logo illegible 1 1
Failed unit weight 1 1
Failed unit weight/osmalaity 1 1
Ink on tablets 1 1
Presence of precipitate 1 1
Resuspension problems 1 1
Failed Moisture Limit 1 1
Undecided 1 1
Total 239 214 4 457
Table 4 Drugs recalled due to stability failure for impurities/degradation/subpotent and stability caused dissolution speciﬁcation failures
that are also on the Chinese EML.
Drug product No. Dosage form Drug product No. Dosage form
Stability failure for impurities/degradation/subpotent (a)
Levothyroxine sodium 21 Tablet Ciproﬂoxacin 1 Ophthalmic solution
Lorazepam 7 Tablet/solution Hydrocortisone 1 Otic solution
Morphine sulfate 6 Extended-release capsule Atropine sulfate 1 Injection
Risperidone 5 Tablet Folic acid 1 Injection
Heparin sodium 4 Injection Fluocinonide 1 Ointment
Amoxicillin, Clavulanate potassium 3 Tablet Amoxicillin 1 Suspension
Oxytocin 3 Injection Ethambutol hydrochloride 1 Tablet
Promethazine hydrochloride 2 Solution Acetaminophen 1 Capsule
Amlodipine besylate 2 Tablet Bupivacaine hydrochloride 1 Injection
Codeine phosphate 1 Solution Epinephrine 1 Injection
Famotidine 1 Tablet Fluorouracil 1 Cream
Stability caused dissolution speciﬁcation failures (b)
Fentanyl 2 Transmucosal/transdermal Phenytoin sodium 1 Extended-release capsule
Metformin hydrochloride 2 Tablet Verapamil hydrochloride 1 Extended-release capsule
Quetiapine fumarate 2 Tablet Diltiazem hydrochloride 1 Extended-release capsule
Ibuprofen 2 Tablet Omeprazole 1 Delayed-release capsule
Sulfamethoxazole, Trimethoprim 2 Suspension Allopurinol 1 Tablet
Albuterol sulfate 2 Extended-release tablet Isoniazid 1 Tablet
Carbamazepine 1 Tablet Alprazolam 1 Tablet
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Table 5 Stability indicating methodology literature search summary.
Drug product Ref. Stability indicating
method
Stability testing method
Acid hydrolysis Alkali hydrolysis Oxidative degradation Thermal degradation Photolytic degradation
Lorazepam 27 HPLC Stability of
extemporaneously
prepared lorazepam
(from Mylan)
suspension (1 mg/mL):
4 1C for 91 days
(recovery: 96.8%)
Stability of
extemporaneously
prepared lorazepam
(from Mylan)
suspension (1 mg/mL):
22 1C for 91 days
(recovery: 94.2%)
Stability of
extemporaneously
prepared lorazepam
(from Watson)
suspension (1 mg/mL):
4 1C for 91 days
(recovery: 99.4%)
Stability of
extemporaneously
prepared lorazepam
(from Watson)
suspension (1 mg/mL):
22 1C for 91 days
(recovery: 88.9%)
/
28 Spectrophotometry 2.5 mg lorazepam:
25 1C for 15 days, with
blister
2.5 mg lorazepam:
25 1C for 15 days,
without blister
2.5 mg lorazepam:
40 1C for 15 days, with
blister
2.5 mg lorazepam:
40 1C for 15 days,
without blister
/
Levothyroxine
sodium
29 HPLC Storage condition 1:
60 1C, 0% RH, 20.9%
O2
Storage condition 4:
RT, 0% RH, 20.9% O2
/ / /
Storage condition 2:
60 1C, 75% RH, 20.9%
O2
Storage condition 5:
RT, 75% RH, 20.9%
O2
Storage condition 3:
60 1C, 0% RH, 0% O2
Storage condition 6:
RT, 0% RH, 0% O2
30 HPLC Stability of
pentahydrate Form:
25 1C/0% RH; 40 1C/
0% RH; 25 1C/60%
RH; 40 1C /75%RH
Stability of dehydrated
Form: 25 1C/0% RH
and 40 1C/0%RH
Drug-excipient
mixtures: excipients
were weighed in 1:1,
1:10, or 1:100 w/w
ratios to the drug; 5%
moisture content;
6071 1C.
/ /
31 HPLC Stability and
hygroscopicity: stored
in open and closed
vials at 40 1C and 75%
RH for a total of
6 months.
Stability with different
excipients: 7 excipients
individually mixed with
95% dibasic calcium
phosphate; 20% (w/v)
aqueous slurries.
Stability with different
excipients at different
pH: 20% (w/v) aqueous
slurries were prepared
using 4 different
excipients. The pH
values were adjusted to
3, 5, 7, 9 and 11 using
0.1 mol/L HCl or
0.1 mol/L NaOH.
Stability with different
diluents: manufactured
with 4 diluents and/or
dibasic calcium
phosphate.
Stability with pH modiﬁers: manufactured with
dibasic calcium phosphate and different basic pH
modiﬁers and acidic pH modiﬁers
Risperidone
(RSP)
32 RP-HPLC 100 mg RSP, 20 mL of
2 mol/L HCl, 45 min at
80 1C (20.90%
degradation)
100 mg RSP, 20 mL of
1 mol/L NaOH, 60 min
at 80 1C (12.70%
degradation)
100 mg RSP, 20 mL of
6% H2O2, 2 h at 80 1C
(13.66% degradation)
100 mg RSP, Petri dish
placed in the hot air
oven for 1 h at 80 1C
(no gradation)
100 mg RSP, Petri dish placed in the UV chamber for
1 h (11.88% degradation)
33 LC 100 mg RSP, 10 mL of
0.1 mol/L HCl, 12 h at
RT (26.89%
degradation).
100 mg RSP, 10 mL of
0.1 mol/L NaOH, 36 h
at RT (17.53%
degradation).
10 mL of 3% H2O2, 4 h
at RT (68.54%
degradation).
1 g RSP, petri dish
kept in oven for 24 h at
80 1C (30.09%
degradation).
1 g RSP, petri dish kept in 200 Wh/m2 in UV light
and 1.2 million lx·h in visible light for 36 h (26.62%
degradation).
F
actors
to
consider
in
developing
individual
pharm
aceutical
product
quality
risk
pro
ﬁ
les
85
Table 5 (continued )
Drug product Ref. Stability indicating
method
Stability testing method
Acid hydrolysis Alkali hydrolysis Oxidative degradation Thermal degradation Photolytic degradation
34 HPLC 25 mg RSP, 10 mL of
5 mol/L HCl, 10 h on
water bath
25 mg RSP, 10 mL
5 mol/L NaOH, 10 h on
water bath
25 mg RSP, 3.5 mL of
3% H2O2, 5 min at
ambient temperature
(11.0% degradation)
25 mg RSP, 72 h at
105 1C
25 mg RSP, kept in a photolytic chamber at
1.2 million/h
Oxytocin (OT) 35 HPLC 0.02 U/mL OT in
1 mol/L HCl and
heated at 90 1C for 1 h
0.02 U/mL OT in
1 mol/L NaOH and
heated at 90 1C for 1 h
/ / /
36 HPLC 20 h (29.8%
degradation)
20 h (13.3%
degradation)
16 h (20.0%
degradation)
105 1C, 5 h (22.2%
degradation)
500-700 ft-candles, 48 h (0.0% degradation)
37 HPLC A 2 mL of 0.1 mol/L
HCl was added to 8 mL
of a 10 IU/mL solution
of OT. This solution
was allowed to stand
for 1 h.
A 2 mL of 0.1 mol/L
NaOH was added to
8 ml of a 10 IU/mL
solution of OT. This
solution was allowed to
stand for 1 h.
A 2 mL of a 3% H2O2
solution was added to
8 ml of a 10 IU/mL
solution of OT. This
solution was placed in a
dark locker for 2 h.
A 10 IU/mL OT
solution was heated to
and maintained at
50 1C for 10 min.
A 10 mL OT solution at a concentration of 10 IU/mL
was exposed to natural sunlight for 8 h.
Amlodipine
besylate
(AML)
38 RP-HPLC 1 mol/L HCl, in a water
bath at 105 1C for
30 min (Recovery:
64.32%)
2 mol/L NaOH, in a
water bath at 105 1C
for 90 min (Recovery:
78.31%)
10% H2O2, in a water
bath 105 1C for 45 min
(Recovery: 32.58%)
Drugs were kept in a
hot air oven at 100 1C
for 48 h
Drugs were exposed to 254 nm and 366 nm of
ultraviolet light for 48 h
39 RP-HPLC 0.1 mol/L HCl, in a
water bath at 80 1C for
1 h. (Recovery:
96.36%)
0.1 mol/L NaOH, in a
water bath at 80 1C for
1 h (Recovery:
16.55%)
3% H2O2, in a water
bath at 80 1C for 1 h
(Recovery: 97.51%)
Solid drugs were
exposed in oven at
80 1C for 2 h.
(Recovery: 94.62)
/
40 HPLC Samples were kept in
stability chamber at
407 2 1C and 7575%
relative humidity for 0,
1, 2, 3, 4.5 months
/ / / /
41 HPLC–DAD 1 mol/L HCl, in a water
bath at 90 1C for
10 min (Degradation
30%)
1 mol/L NaOH, in a
water bath at 60 1C for
10 min (Degradation
35%)
5% H2O2, in a water
bath at 80 1C for 2 h
(Degradation 25%)
100 mg AML was kept
in an oven at 90 1C for
18 h (No degradation)
100 mg AML was subjected to UV irradation at
254 nm for 60 h (No degradation)
42 HPTLC Using 9 mL of AML
solutions and 0.5 mL of
5 mol/L HCl and
keeping it overnight
(0.1 mol/L HCl,
negligible; 5 mol/L
HCl 48.93% decrease
in peak area)
Using 9 mL of AML
solutions and 0.5 mL of
5 mol/L NaOH and
keeping it overnight
(0.1 mol/L NaOH,
negligible; 5 mol/L
NaOH, 42.10%
decrease in peak area)
Using 9 mL of AML
solutions and 0.5 mL of
30% H2O2 and keeping
at room temperature for
72 h (3% hydrogen
peroxide, negligible; 30
hydrogen peroxide,
10.74 decrease in peak
area)
The standard drug in
solid form was placed
in oven at 80 1C for
24 h. (Less than 1%)
Exposing the bulk drug to UV light 200 Wh/m2
followed by Cool Fluorescent light up to illumination
of 1.2 million Lx·h (Less than 2%)
Famotidine 43 RP-HPLC To 0.49 mL of
famotidine stock
To 0.49 mL of
famotidine stock
To 0.49 mL of
famotidine stock
To 0.49 mL of
famotidine stock
/
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solution 3 mL of
0.1 mol/L HCl was
added and kept at
normal condition for
90 min (1.51%
degradation)
solution 3 mL of
0.1 mol/L NaOH was
added and kept at
normal conditions for
90 min (1.28%
degradation)
solution 1 mL of 3% w/v
H2O2 was added
(1.49% degradation)
solution 3 mL of the
dilute was added and
kept at a reﬂex
condiction for
60 minutes (1.19%
degradation)
44 RP-HPLC 0.1 mol/L HCl for 24 h
at TR (6.56%
degradation)
0.1 mol/L NaOH for
24 h at RT (8.58%
degradation)
1% H2O2 for 24 h at
TR (18.63%
degradation)
45 1C for 36 h (11.60%
degradation)
Exposed in the presence of light (14.61%
degradation)
45 RP-HPLC (97.46%) (peak distorted) (104.32%) / (94.08%)
46 HPTLC The drug (10 mg) was
dissolved in 10 mL of
1 mol/L HCl solution
and kept for 8 h at RT
in dark. (96.0274.09%
Recovery)
The drug (10 mg) was
dissolved in 10 mL of
1 mol/L NaOH solution
and kept for 8 h at RT
in dark. (86.0575.39%
Recovery)
10 mg drug was
dissolved in 10 mL of
methanolic solution of
H2O2 (10%, v/v) and
kept for 8 h at RT in
the dark.
(75.34711.08%
Recovery)
The powdered drug
was stored for 3 h at
55 1C (93.79710.72%
Recovery)
Drug solution was exposed to direct sunlight for
3 days (GMT, 09:00-17:00 h at 30 1C, total 24 h)
(71.7077.65% Recovery)
47 HPLC 0.1 mol/L HCl, for
20 min
0.1 mol/L NaOH for
20 min
/ / /
Fluocinonide 48 LC 1 mol/L HCl, 48 h
(86.5% of active
substances)
0.1 mol/L NaOH,
30 min (74.7% of
active substances)
5% H2O2, 48 h (90.8%
of active substances)
60 1C, 10 days (99.3%
of active substances)
carried out as per ICH Q1B, 10 days (99.2% of active
substances)
Amoxicillin 49 LC to 15 mL of 10 μg/mL
solution, 15 mL of
1 mol/L HCl was added
and heated for 2 h at
70 1C (20%-25%
degradation)
to 15 mL of 10 μg/mL
solution, 15 mL of
0.05 mol/L NaOH was
added and heated for
2 h at 70 1C (15%-20%
degradation)
to 15 mL of 10 μg/mL
solution, 15 mL of 20%
H2O2 was added and
heated for 2 h at 70 1C
(5%-7% degradation)
/ 15 mL of 10 μg/mL solution was exposed to artiﬁcial
white light (12,000 lx for 144 h, at 25 1C) and UV
light (254 nm for 3 h) (5%-7% degradation)
50 HPLC 0.5 mol/L HCl (6.65%
degradation)
0.1 mol/L NaOH
(6.21% degradation)
0.1% (v/v) H2O2
(5.01% degradation)
(13.12% degradation) (8.59% degradation)
/, not applicable.
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Table 6 Summary of product recalls by dosage forms due to
stability caused impurities/degradation/subpotent and stability
caused dissolution failures.
Administration route Dosage from No.
Stability caused impurities/degradation/subpotent (a)
Oral Tablet 73
Solution 9
Extended-release capsule 6
Capsule 4
Extended-release tablet 1
Delayed-release capsule 1
Chewable tablet 1
Suspension 1
Total 97
Parenteral Injection 24
Total 24
Topical Ointment 4
Lotion 2
Cream 2
Solution 2
Gel 1
Total 11
Others Ophthalmic solution 3
Otic solution 2
Suppository 2
Inhalation solution 1
Total 8
Stability caused dissolution failures (b)
Oral Extended-release tablet 20
Tablet 14
Extended-release capsule 10
Delayed-release capsule 2
Suspension 2
Delayed-release tablet 2
Transmucosal 1
Total 51
Topical Transdermal system 1
Total 1
Wei Xu et al.88market was examined. As is shown in Table 7, for solid oral
products, the products excluded from the data pool for the reasons
described in Methodology amounted to about 7% of the total
product volume for products designated as “ordinary” which
means immediate-release, and about 0.25% for products desig-
nated as “long-acting” which means modiﬁed-release, over the
3 years. Modiﬁed-release product volume is about 8.9% of the
total for solid oral product volume.
A total of 52 products had been recalled for dissolution failures that
occurred during stability studies. Of these 48 were solid oral dosage
forms (2 were suspensions, 1 was a transdermal product and 1 was a
transmucosal product). Of the 48, 34 were modiﬁed-release dosage
forms and 14 were immediate-release dosage forms. Based on simple
number of products recalled, 71% (34/48) were extended-release
dosage forms, however when weighted for 2013 corrected market
volume, 96%(2) of recalls were due to modiﬁed-release products. As
might be expected, the vast majority of dissolution failures for solid
oral products occur with modiﬁed-release products where the formula-
tion seeks to exert control over drug release and dissolution.
Of the 14 recalls for dissolution failure of immediate-release
solid oral products, 2 were extensions of other recalls making a(2)(34/0.089)/(34/0.089þ14/0.911) 100%¼96%.total of 12 unique failures, as are shown in Table 8. All were
tablets with no capsule product among the recalls. Three were
brand products and 9 were generics, approximately the same ratio
as marketed product volume. Eight of the 12 were high potency
tablets (that is with a high API loading) including 4 very high
potency products of high solubility drugs, indicating that tablet
formulation is important in this type of product. This suggests that
API solubility and tablet potency are not predictors of dissolution
failure in immediate-release solid oral products. The high propor-
tion of high and very high potency products suggests that
formulation and possible changes in formulation on aging may
be important predictors of dissolution failure.
The 38 recalls for dissolution failure of modiﬁed-release solid
oral products contained 31 unique recalls, as shown in Table 9. Of
these, 4 were delayed-release products and 27 were extended-
release products. Eleven were capsule products and 20 were tablets
with 8 brand products and 23 generics, approximately the same
ratio as marketed product volume. Nineteen (61.3%) of these
products are matrix type extended-release tablets, 8 (25.8%) are
polymer coated multiparticulate type extended-release capsules,
and of the delayed-release products 2 (6.45%) are tablets and 2
(6.45%) are polymer coated multiparticulate type capsules. There
is no apparent pattern to the product type of these failures and the
underlying causes of failure need more information than can be
gleamed from the recall reason descriptions.
3.5. The generally regarded high risk proﬁles of sterile
preparations are mostly due to compounding failures
Over the period 2011–2013, 1770 products (43.6% of total
recalled products) were recalled due to compounding failures. Of
all these 1770 recalled products, 850 (48.0%) were due to potential
for penicillin cross contamination and 610 (34.5%) were due to
lack assurance of sterility. These compounding recalls were fairly
evenly spread across the 3 year time period strongly suggesting
that compounding remains a signiﬁcant public health threat.
Of the total 457 recalled products picked out due to potential
product speciﬁc risks, only 7 were related to sterility. These were
two due to lack of assurance of sterility, two because of microbial/
mold contamination, and three for preservative efﬁcacy failure.
These results may indicate that the intensity of inspectional focus
on high risk manufacturing is paying dividends.
3.6. Complex manufacturing processes lead to more problems
Among the 457 products recalled, the 12 peel force failures and
6 adhesion failures (in Table 3) were all related to transdermal
delivery systems and summed to 18 which ranked 5th among all the
recall reasons following impurities/degradation/subpotent, presence
of foreign substances, dissolution and tablet weight. This dispropor-
tionate number of transdermal patch failures suggested that complex
manufacturing processes did in fact lead to more problems.4. Discussion
We set out to determine what would be required to establish a
system of product speciﬁc risk proﬁles using the Chinese EML as
a template for products, restricting our analysis to conventional
chemical and biological drugs of commercial manufacture. Due to
the reason that the marketed drug product problem information in
China is not readily available publically, we turned to the US
Table 7 USA pharmaceutical product volume categorized based on dosage forms, 2013. Source: IMS Health
Dosage form Total After exclusiona Percentage (%)
Oral solid ordinary 202,145,656 187,683,992b 92.85%
Oral solid long-acting 18,170,650 18,122,975c 99.74%
Oral liquid ordinary 20,912,828 14,993,005 71.69%
Oral liquid long-acting 218,016 218,016 100.00%
Parenteral ordinary 2,698,287 2,518,343 93.33%
Parenteral long-acting 193,624 193,624 100.00%
Rectal systemic 50,758 50,758 100.00%
Nasal systemic 98,267 92,578 94.21%
Other systemic 1,608,857 1,608,857 100.00%
Transdermal 743,270 743,270 100.00%
Oral topical 2,208,350 995,086 45.06%
Topical, dermatological 51,420,649 26,091,630 50.74%
Ophthalmic 31,683,267 29,108,301 91.87%
Otic 1,887,305 1,879,664 99.60%
Nasal topical 14,815,822 9,715,348 65.57%
Lung administration 19,112,246 19,082,755 99.85%
Vaginal/Intra-uterine 468,622 465,408 99.31%
Non-human use and other N/A N/A N/A
Unknown N/A N/A N/A
N/A, not available.
aProducts not identify dosage form, whether it is a drug or otherwise not relevant were excluded.
b,cModiﬁed-release product volume is about 8.9% of the total for solid oral product volume, b/(bþc).
Table 8 12 immediate-release solid oral products dissolution failures.
Drug product Strength (mg) Recall No. Dosage form Brand or
generic
API solubility
(mg/mL)
Tablet potency Ref.
Valacyclovir hydrochloride 1000 D-164-2011 Tablet Generic 174 (very high) Very high 2
Carbamazepine 200 D-381-2011 Tablet Generic 0.01–0.12 (low) High 2,51–54
Allopurinol 300 D-1280-2011 Tablet Generic 0.1–0.5 (high) High 2,55
Metformin hydrochloride 1000 D-1113-2012 Tablet Generic 100–300 (very high) Very high 2,56
850 D-1114-2012 Tablet Generic 100–300 (very high) Very high 2,56
Moexipril hydrochloride 7.5 D-007-2013 Tablet Generic o0.1 (low) Low 57
Quetiapine fumarate 25 D-059-2013 Tablet Generic 10 (low) Medium 2
Isoniazid 300 D-174-2013 Tablet Generic 125 (high) High 2
Estradiol acetate 1.8 D-851-2012 Tablet Brand 0.01 (low) Low 2
Potassium citrate 540 D-867-2012 Tablet Generic 1540 (very high) High 58
Alprazolam 0.5 D-1197-2012 Tablet Brand 0.01–0.11 (low) Very low 2,59,60
Ibuprofen 200 D-1216-2012 Tablet Brand 0.01–0.05 (low) High 2,61
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able on FDA's website.
First we determined from the Orange Book that the US market was
in fact representative of the drug products on the Chinese EML, ﬁnding
that 69.4% of the EML products were also approved in the US. We
then turned to data about drug product market performance choosing to
focus on recalls as the most fruitful source of data on marketed product
problems. We analyzed recall data from calendar years 2011, 2012 and
2013, the most recent complete sets of recall data. Using the data, we
expanded the FDA recalls into number of products recalled. This data
was then reduced by excluding from the study product data pool that
were not recalled for a product speciﬁc failure, products where we
could not assign a speciﬁc recall reason, and product that were not
relevant product types, for example dental products or cosmetics. This
enriched the recall data set to those products where a product speciﬁc
failure was the cause of the recall. Of the enriched data set of 457product batches, we further analyzed the reason for recall and
categorized them as stability related, manufacturing related, or
laboratory testing related. Of the 239 product batches that exhibited
stability failures, 192 were for two reasons, impurities/degradation/
subpotent (140) and dissolution failures (52). The other product related
stability failures were for reasons such as particle size (4), AET failure
(3), viscosity (3), microbial contamination (2), pH speciﬁcation failure
(2), etc. So we conclude that for product speciﬁc risk factors,
degradation and dissolution failures stand out well above all other
causes which show only a slight signal of failure potential. Therefore
methods of assessing the likelihood of degradation and assessing the
causes behind the dissolution failures in modiﬁed-release products
would add signiﬁcantly to a scheme of product speciﬁc risk proﬁling.
A literature search based on a sample of 8 candidate drugs from
the study product data pool did not reveal any methodology that is
directed at predicting the relative chemical stability of drug
Table 9 31 modiﬁed-release solid oral products dissolution failures.
Drug products Strength (mg) Recall no. Dosage form Brand or generic
Nisoldipine 25.5 D-210-2011 ER Matrix type Tablet Brand
17 D-211-2011 ER Matrix type Tablet Brand
17 D-1398-2012 ER Matrix type Tablet Brand
Alprazolam 2 D-726-2011 ER Matrix type Tablet Brand
2 D-1361-2012 ER Matrix type Tablet Generic
Doxazosin mesylate 4 D-1186-2012 ER Matrix type Tablet Brand
Acamprosate calcium 333 D-1332-2012 DR Coated tablet Tablet Brand
333 D-291-2011 DR Coated tablet Tablet Brand
Potassium citrate 10 D-773-2011 ER Matrix type Tablet Generic
5 D-774-2011 ER Matrix type Tablet Generic
Albuterol sulfate 4 D-884-2012 ER Matrix type Tablet Generic
4 D-885-2012 ER Matrix type Tablet Brand
Bupropion hydrochloride 300 D-1328-2012 ER Matrix type Tablet Generic
150 D-1329-2012 ER Matrix type Tablet Generic
300 D-175-2013 ER Matrix type Tablet Generic
300 D-248-2013 ER Matrix type Tablet Generic
300 D-917-2013 ER Matrix type Tablet Generic
300 D-855-2013 ER Matrix type Tablet Generic
Venlafaxine hydrochloride 225 D-1067-2013 ER Matrix type Tablet Generic
Budesonide 3 D-452-2013 DR Polymer coated multiparticulate type Capsule Generic
Diltiazem hydrochloride 360 D-145-2013 ER Polymer coated multiparticulate type Capsule Generic
Dextroamphetamine sulfate 5 D-171-2013 ER Polymer coated multiparticulate type Capsule Generic
5 D-172-2013 ER Polymer coated multiparticulate type Capsule Generic
5 D-173-2013 ER Polymer coated multiparticulate type Capsule Generic
Methylphenidate hydrochloride 20 D-847-2013 ER Polymer coated multiparticulate type Capsule Generic
30 D-848-2013 ER Polymer coated multiparticulate type Capsule Generic
40 D-849-2013 ER Polymer coated multiparticulate type Capsule Generic
Phenytoin sodium 100 D- 66,014-001 ER Matrix type Capsule Generic
Verapamil hydrochloride 180 D-1116-2012 ER Polymer coated multiparticulate type Capsule Generic
Nifedipine 60 D-449-2011 ER Matrix type Tablet Generic
Omeprazole 20 D-009-2014 DR Polymer coated multiparticulate type Capsule Generic
Wei Xu et al.90products. Literature was all directed at the development of stability
indicating analytical methods which used forced or stress degrada-
tion to produce samples for developing the method. The aim was
to generate degradants no matter how severe the conditions
applied. What is required for a product speciﬁc risk assessment
is methodology that can predict how chemically fragile a drug
substance and drug product are under conditions that it could
reasonably be exposed to normal handling and use. It is possible
that the drug products that have shown failures can be compared
with those that have not shown failures to aid in developing
suitable methodology.
To further assess the risk of dissolution failure the ﬁrst step is to
determine what type of modiﬁed-release formulations resulted in
failures to see if some formulation types are more prone to this failure
mode. We weighted the data from the drug recall information using the
products volume data on US market and found that 96% of the
dissolutions failures were related to modiﬁed-release oral dosage forms.
Analysis of the recall data for manufacturing and/or product class
failures supports the idea that complex manufacturing methodolo-
gies lead to increased post marketing product problems. The number
of recalls of transdermal products linked to failure of adhesives is a
strong signal that complex products are more fragile and subject to
relatively more on-market failures. Parenteral products yielded
many failures for particulate matter, the origin of some ascribed
to packaging components but many undeﬁned. There were almost
no sterility failures which might suggest that the intensive oversight
of sterile product manufacturing has almost eliminated sterilityissues in commercially manufactured product in the US. This is a
conclusion that is not easily extrapolated to other areas where
oversight and inspectional practices may vary considerably.5. Conclusions
We established that there is a similarity in the set of drugs on the
Chinese EML and the set of drugs registered in the US. Using US
recall data from a 3 year period, we extracted recalls that are product
speciﬁc, i.e., the product failure relates to a property of the speciﬁc
product. We found two causes for product speciﬁc recalls over all
others, degradation and dissolution failure. In addition, manufactur-
ing complexity, an established risk factor, also results in a relatively
high recall rate. Literature search failed to ﬁnd any methodology for
assessing relative risk of product degradation, so such methodology
needs to be developed. Further work on dissolution failures targeted
at determining the types of product that fail would enhance
understanding of this important cause of product failure.Acknowledgments
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